STORY SUMMARY

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

This is a brief summary of reporting from FDA Press Releases. Read the original for the full article and context.

Read original reporting ↗

More from FDA Press Releases · Latest headlines